ADRX-0405 is uniquely being tested during its 1a/b clinical trials. ADRX-0405 is labeled as a STEAP1 ADC (primarily ...

Life sciences marketing has long revolved around physicians. Traditionally seen as the gatekeepers of prescribing power, ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

In today’s fast-paced, innovation-fueled biopharma landscape, the traditional model of C-suite leadership is being turned on ...

One of the concerns people have when they hear FDA is using AI in the drug approval process is that many people don't have a ...

The Medipost CEO discusses developing treatments for knee osteoarthritis and other conditions.

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests ...

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...